article thumbnail

Tiziana Life Sciences plans to assess intranasal foralumab for long Covid

Pharmaceutical Technology

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.

article thumbnail

Cloudbyz Recognized in Everest Group’s 2024 PEAK Matrix® for Life Sciences CTMS Solution

Cloudbyz

We are deeply honored to be recognized in Everest Group’s PEAK Matrix® for Life Sciences CTMS solutions,” said Dinesh Kashyap, CEO and Founder of Cloudbyz. Our mission is to enable faster, more efficient trials, ultimately supporting the delivery of life-saving therapies.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

In the life sciences sector, one country is significantly outstripping others for FDI. Data shows that almost 40% of all life sciences subsidiaries are located in the US. After all, around a third of the world’s leading life sciences corporations have their headquarters in the country.

article thumbnail

Patient-Centric Marketing in the Life Science Industry: Putting the Focus on Patient Needs

Pharma Mirror

Compliance with complex laws and regulations, like Direct-to-Consumer Advertising (DTCA) Rules or the Health Insurance Portability and Accountability Act (HIPAA), can be quite daunting. And it is not hard to see why.

article thumbnail

Hidden compliance risks for life sciences companies

pharmaphorum

The life sciences history industry has some unique challenges when it comes to compliance. Early life science pioneers in foreign markets earned a reputation for lax ethical behaviour, making them a prime target for regulators. Seeing through these tricks is a difficult task, but not impossible.

article thumbnail

How the New EU AI Act Will Impact Clinical Trials in the Life Sciences?

Cloudbyz

This Act is poised to significantly change the clinical trials landscape within the life sciences sector. As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation.

article thumbnail

6 Life Science Technology Trends for 2023

XTalks

The life science industry is constantly evolving, making it difficult to stay ahead of the curve. Digital transformation is burgeoning and we aim to cover some of the dominant emerging technologies that are currently running the life science industry by storm.